BioWorld Today: Clinic Roundup--Chimerix Inc.
May 17, 2013 - BioWorld Today
Chimerix Inc., of Durham, N.C., said it presented data demonstrating CMX001’s high barrier to viral resistance in the prevention and treatment of cytomegalovirus (CMV) infection. The data were presented at the International Society for Antiviral Research’s 26th International Conference on Antiviral Research. CMX001 is an investigational oral nucleotide analog lipid-conjugate that has a broad spectrum of antiviral activity against double-stranded DNA viruses. In the Phase II study, different doses of CMX001 were explored for potential CMV prevention in at-risk patients. Across a spectrum of doses, there were no treatment-emergent mutations detected that are associated with phenotypic resistance to CMV antivirals.